uacoopera

PSA purification and concentration from urine samples for non-invasive early stage diagnosis of prostate cancer

Posted by UACOOPERA from uacooperaResponsive · Patents for licensing · Portugal

Summary of the technology

New method for the pretreatment of human urine sam-ples, comprising the simultaneous extraction, concentration and purification of the prostate-specific antigen (PSA), a prostate cancer biomarker.
In this technology, aqueous biphasic systems composed of ionic liquids and salts are used. These systems allow the selective extraction of PSA and to obtain high con-centration/enrichment factors, enabling the quantification of PSA using less sophisticated, cheaper and more affordable equipment.

UATEC - Unidade de Transferência de Tecnologia
UATEC - Unidade de Transferência de Tecnologia

CONTEXT

The PSA (tumor biomarker) quantification in serum is currently used for the early stage diagnosis of prostate cancer (PCa). However, most of the available techniques for PSA quantification require extensive sample processing and expensive analysis (e.g. ELISA) that are mostly unavailable in low-income countries in which the mortality associated to PCa is higher. Furthermore, blood is an invasive matrix that requires certified personnel for collection. PSA is also present and can be detected in urine, a less invasive matrix. However, the current methods for its quantification in urine are highly expensive and cumbersome.

The developed cost-effective technology allows the simultaneous specific extraction, concentration and purification of PSA from urine samples using aqueous biphasic systems (ABS) composed of ionic liquids and salts. This technology allows a lossless and contaminant-free extraction and high concentrated factors in a single-step.

APPLICATIONS

QUANTIFICATION OF PSA AND ITS ISOFORMS IN URINE

EARLY STAGE DIAGNISTICS AND ASSESSMENT OF PROSTATE CANCER TREATMENT EVOLUTION AND EFFICIENCY

BENEFITS

NON-INVASIVE: this technology allows the use of urine as sample for PSA quantification.

SELECTIVE AND EFFECTIVE EXTRACTION, PURIFICATION AND CONCENTRATION OF PSA AND ITS ISOFORMS, allowing the use of urine for primary or complementary prostate cancer diagnosis and evaluation.

CHEAPER AND SIMPLER ANALYTIC TECHNIQUES: as high concentration factors are obtained, it is possible to quantify PSA with simpler analytical techniques, and requiring less laborious pre-treatment techniques.

POTENTIALLY HIGHER PREDICTIVE VALUE thanks to PSA and respective isoforms specific extraction.

IP RIGHTS

Provisional patent application filed in Portugal (priority date: 29-10-2018).

DEVELOPMENT STAGE

TRL 4: small-scale laboratory prototype.

The method was tested in real urine samples from healthy individuals, to which PSA was added into known concentrations. A study with samples from patients in different prostate cancer stages, with known blood PSA levels is ongoing. The required minimum urine sample volume is 25mL.

It is expectable that with the appropriate support from partners, 10 months will be sufficient to scale-up and to introduce de technology in the market.

KEYWORDS

Prostate specific antigen (PSA)

Ionic liquids

Aqueous biphasic systems (ABS)

Pretreatment

Urine

DEVELOPED BY

Researchers from Aveiro Institute of Materials (CICECO) from the University of Aveiro.

BUSINESS OPPORTUNITY

Licensing agreement.

PARTNERSHIP

The University of Aveiro seeks industrial partners within health area, with interest in the development and/or commercialization of new diagnostic/prognostic tests or of clinical analysis.

Technology #CI18012

Intellectual property status

Patent already applied for
115115
Portugal

Technology Owner

uacoopera

Technology Transfer Office

UACOOPERA University of Aveiro

Technology Transfer Office at uacoopera

Additional information (attached documents)

Related keywords

  • Physical Sciences and Exact Sciences
  • Chemistry
  • Organic Chemistry
  • Separation Technologies
  • Extraction
  • Biological Sciences
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Diagnostics, Diagnosis
  • Medical Technology / Biomedical Engineering
  • Biology / Biotechnology
  • Genetic Engineering / Molecular Biology
  • Biochemistry / Biophysics Market
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Other ( Diagnostic related )
  • Other diagnostic
  • Molecular diagnosis
  • Differential diagnosis
  • Clinical Medicine
  • Oncology
  • Medical equipment
  • Diagnostic equipment

About uacoopera

Technology Transfer Office from Portugal

The University of Aveiro is a young and innovative university, which fosters entrepreneurship and technology and knowledge transfer, with expertise in a wide range of knowledge areas namely IT, Life Sciences (Biology, Chemistry, Biochemistry, Health, Environmental Sciences), Nanotechnology and Materials Science, Mechanics, Physics, Mathematics, Building, Design and Management. uacoopera is the Technology Transfer Office of University of Aveiro. This office engages in value adding activities such as start-up and spin-off creation, support to university-industry cooperation (sponsored research and consultancy services), IP protection and prosecution, licensing, marketing, among others. It covers four main interrelated functional areas – Intellectual Property Management, Licensing, Entrepreneurship, and Industry Liaison.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.